News CGT Global Appoints Charlotte Ivancic to Board of Advisors, Strengthening Strategic Leadership in Cell and Gene Therapy Policy and Market Access May 21, 2026 Read More → Leukopak vs PBMC vs Whole Blood: What’s the Difference and Which One Do You Need? May 14, 2026 Read More → T Cell Activation in Cell Therapy: Why T Cell Activation Fails Without the Right Starting Material Apr 17, 2026 Read More → Why CGT Global Is Positioned to Support the Next Wave of Cell and Gene Therapies Mar 5, 2026 Read More → Bulk CD34+ Isolation from Mobilized Leukopaks: GCSF vs GCSF + PLX vs PLX Feb 24, 2026 Read More → B Cell CAR T in Autoimmune Disease Breaks for Predictable Operational Reasons Jan 26, 2026 Read More → Blood Types Explained Jan 16, 2026 Read More → From Donor Recall to Data Integrity: The Operational Backbone of Ex Vivo Cell Therapy Jan 14, 2026 Read More → Everything CGT Global Offers: Starting Materials, Isolated Cells, and Clinical Grade Supply Jan 12, 2026 Read More →
